<sup>90</sup>Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide TherapyYusuf Menda, M. Sue O’Dorisio, Mark T. Madsen et al.|Journal of Nuclear Medicine|2018Cited by 51
Safety and accuracy of <sup>68</sup>Ga-DOTATOC PET/CT in children and young adults with solid tumors.Chenue Abongwa, Yusuf Menda, Parren McNeely et al.|PubMed|2017Cited by 18
Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine TumorsSilvia N. Ghobrial, M. Sue O’Dorisio, Yusuf Menda et al.|Pancreas|2020Cited by 10
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patientsCamila Gadens Zamboni, Ahmad Shariftabrizi, Ayca Dundar et al.|EJNMMI Reports|2024Cited by 9
Clinical Utility of Pretreatment and 3-Month <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive RadiationZachary Mayo, Carryn M. Anderson, Steven N. Seyedin et al.|Annals of Otology Rhinology & Laryngology|2019Cited by 4